Programa
Martes 18 de mayo
14.30 h. Bienvenida y Presentación.
Speakers:
Dr. D. Pedro Peréz Segura
Oncología Médica-HCSC y Universidad Complutense Madrid.
Dr. D. Alberto Ocaña
Oncología Médica-HCSC y Universidad Castilla-La Mancha.
Dr. D. Guillermo Velasco Díez
Universidad Complutense Madrid.
15.00 h. Session 1. Novel Therapies and Multi-omics Approaches
Chairs:
Prof. D. Eduardo Díaz-Rubio
Real Academia Nacional de Medicina, Madrid.
Dr. D. Emiliano Calvo
Clara Campal, Madrid.
Speaker:
Dr. D. Alberto Ocaña
Oncología Médica-HCSC y Universidad Castilla-La Mancha.
15.00 h. Novel therapies and combinations on the horizon
Speaker:
Dr. D. Lajos Pusztai
Yale University, CT.
15.30 h. Identification of Novel Targets with Multi-omics and AI
Speaker:
Dª. María Muñoz Caffarel
Biodonostia
16.00 h. Targeting tumour-promoting inflammation in breast cancer
Speakers:
Prof. D. Eduardo Díaz-Rubio
Real Academia Nacional de Medicina, Madrid.
Dr. D. Emiliano Calvo
Clara Campal, Madrid.
Dr. D. Alberto Ocaña
Oncología Médica-HCSC y Universidad Castilla-La Mancha.
Dr. D. Lajos Pusztai
Yale University, CT.
Dª. María Muñoz Caffarel
Biodonostia
16.30 h. Discussion
17.00 h. Session 2. Breast Cancer and Novel Vulnerabilities
Chairs:
Dr. D. Atanasio Pandiella
CIC-Salamanca
Dr. D. José Ángel García Sáenz
HU Clínico San Carlos, Madrid.
Speaker:
Dr. D. Philippe Bedard
Princess Margaret Cancer Center. Toronto.
17.00 h. Targeting HER2 in Breast Cancer: novel opportunities
Speaker:
Dr. D. Miguel Martín Jiménez
Hospital Gregorio Marañón, Madrid .
17.30 h. Novel Opportunities in Triple Negative Breast Cancer
Speaker:
Dr. D. José Ángel García Sáenz
HU Clínico San Carlos, Madrid.
18.00 h. Strategies in Luminal Tumors
Speakers:
Dr. D. Atanasio Pandiella
CIC-Salamanca
Dr. D. José Ángel García Sáenz
HU Clínico San Carlos, Madrid.
Dr. D. Philippe Bedard
Princess Margaret Cancer Center. Toronto.
Dr. D. Miguel Martín Jiménez
Hospital Gregorio Marañón, Madrid .
18.30 h. Discussion
Miércoles 19 de mayo
15.00 h. Session 3. Ginecological Tumors and Melanoma
Chair:
Dr. D. Antonio Casado Herráez
Hospital Clínico San Carlos Madrid.
Speaker:
Dr. D. Antonio González Martín
CUN-Madrid.
15.00 h. Updates in Ovarian Cancer
Speaker:
Dr. D. Gennaro Ciliberto
Istituto Nazionale Tumori IRCCS.“Fondazione G. Pascale”, Naples, Italy; University of Catanzaro “Magna Graecia”, Catanzaro, Italy.
15.30 h. New Options in Melanoma
Speaker:
Dr. D. Jesús Paramio
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) y Biomedical Research Institute I+12.
16.00 h. When Epigenetics met immunotherapy, A tale of bladder cáncer
Speakers:
Dr. D. Antonio Casado Herráez
Hospital Clínico San Carlos Madrid.
Dr. D. Jesús Paramio
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) y Biomedical Research Institute I+12.
Dr. D. Antonio González Martín
CUN-Madrid.
Dr. D. Gennaro Ciliberto
Istituto Nazionale Tumori IRCCS.“Fondazione G. Pascale”, Naples, Italy; University of Catanzaro “Magna Graecia”, Catanzaro, Italy.
16.30 h. Discussion
17.00 h. Award of acknowledgement to the Scientific International Trajectory in Oncology (granted by the Scientific Committee and Fundación Cris contra el Cáncer)
17.15 h. Session 4. Urologic Cancer
Chairs:
Dr. D. Enrique Grande
Hospital MD Anderson. Madrid.
Dra. Dª. Verónica Torrano Moya
CiC Biogune.
Speaker:
Dr. D. Ian Tannock
UHN Toronto.
17.15 h. Novel Therapies in Prostate Cancer: lessons learned
Speaker:
Dr. D. Javier Puente Vázquez
Hospital Clínico San Carlos, Madrid.
17.45 h. Immunotherapies in Bladder Cancer
Speaker:
Dra. Dª. Verónica Torrano Moya
CiC Biogune.
18.15 h. Targeting PGC1α-driven transcriptional landscape for personalized
Speaker:
Dr. D. Francisco X. Real
CNIO. Madrid.
18.45 h. Bladder Cancer Subtypes: therapeutic implications
Speakers:
Dr. D. Enrique Grande
Hospital MD Anderson. Madrid.
Dra. Dª. Verónica Torrano Moya
CiC Biogune.
Dr. D. Ian Tannock
UHN Toronto.
Dr. D. Javier Puente Vázquez
Hospital Clínico San Carlos, Madrid.
Dr. D. Francisco X. Real
CNIO. Madrid.
19.15 h. Discussion
Jueves 20 de mayo
15.00 h. Session 5. Lung Cancer and Traslational Oncology
Chairs:
Dra. Dª. Pilar Garrido
HU Ramón y Cajal, Madrid.
Dra. Dª. Patrizia Agostinis
University of Leuven.
Speaker:
Dr. D. Luis Montuenga Badía
CIMA, Pamplona.
15.00 h. Searching for novel targets in lung cancer. The potential of YES1
Speaker:
Dra. Dª. Enriqueta Felip
Vall D´Hebron, Barcelona.
15.30 h. Strategies After Progression
Speaker:
Dr. D. Luis Paz Ares
Hospital 12 Octubre, Madrid.
16.00 h. Novel Immunotherapies
Speaker:
Dra. Dª. Patrizia Agostinis
University of Leuven.
16.30 h. Targeting the tumor vasculature by harnessing autophagy
Speaker:
Dr. D. Guillermo Velasco Díez
Universidad Complutense Madrid.
17.00 h. Towards the utilization of cannabinoids as anticancer agents
Speakers:
Dra. Dª. Pilar Garrido
HU Ramón y Cajal, Madrid.
Dra. Dª. Patrizia Agostinis
University of Leuven.
Dr. D. Luis Montuenga Badía
CIMA, Pamplona.
Dra. Dª. Enriqueta Felip
Vall D´Hebron, Barcelona.
Dr. D. Luis Paz Ares
Hospital 12 Octubre, Madrid.
Dr. D. Guillermo Velasco Díez
Universidad Complutense Madrid.
17.30 h. Discussion
18.00 h. Keynote Lecture. “Kinase drug discovery 20 years after Imatinib: progress and future directions”
Chairs:
Dr. D. Guillermo Velasco Díez
Universidad Complutense Madrid.
Sir Philip Cohen
Dundee University.
